- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02339402
Non Invasive Prenatal Testing (NIPT) of Single-gene Disorders
NON-INVASIVE PRENATAL TESTING (NIPT) OF FETAL SINGLE-GENE DISORDERS IN MATERNAL BLOOD
Study Overview
Status
Conditions
Detailed Description
Rationale: Conventional prenatal diagnosis (PND) for single-gene disorders requires invasive procedures, either chorionic villus sampling between 11 and 14 weeks gestation or amniocentesis after 15 weeks. Although these approaches to obtain foetal DNA currently provide the golden standard for PND, the invasive procedures carry a risk of miscarriage of 0.5-1%. A reliable non-invasive alternative has long been sought. Circulating cell-free foetal (cff) nucleic acids (DNA and RNA), which are present in maternal blood during pregnancy, can be used for non-invasive prenatal testing (NIPT). NIPT for some chromosomal anomalies (trisomy 21, 13, 18) is now validated. NIPT for other chromosomal anomalies is still under development. NIPT of single-gene disorders is technically very challenging, due to the predominance of maternal DNA sequences, Some small studies have shown that a very limited number of monogenic genetic disorders can currently be diagnosed in maternal blood. In general de novo mutations in the foetus and paternally transmitted disorders are less difficult to diagnose than maternally transmitted disorders.
In this study, the investigators aim to develop non-invasive targeted molecular analysis using cell free fetal (cff) DNA and cff RNA for single-gene disorders, in pregnant women referred to the departments of Clinical Genetics of Maastricht University Medical Centre (MUMC+) and Radboud University Medical Centre (RUMC) for conventional PND. The investigators will contribute to literature by confirming earlier published results, and by adding other single-gene disorders or mutations to the list of disorders for which the possibility of the use of cff DNA will be examined.
Objective: Developing targeted non-invasive prenatal analysis for single-gene disorders using cff DNA and RNA in maternal plasma.
Study design: This study is a proof of concept study in which we aim to demonstrate that molecular analysis can indicate the presence or absence of (a) mutant allele(s) in maternal plasma.
Study population: Pregnant women (≥18y) referred to the Department of Clinical Genetics of MUMC+ or RadboudUMC for conventional PND, for one of the following reasons:
- The fetus is at high risk of having inherited a dominant or recessive disorder of his/her affected parent(s).
- The fetus at risk of having a de novo disorder on the basis of ultrasonography findings.
Main study endpoints: Does targeted molecular analysis of cff DNA and RNA indicate
- the presence or absence of (a) mutant allele(s) in maternal plasma
- the presence of a sufficient concentration of foetal nucleic acids in the maternal plasma to reliably diagnose the monogenic disorder Nature and extent of the burden and risks associated with participation and benefit: minimal burden: one moment of blood sampling for the pregnant woman and her partner. In most cases the blood sampling will be combined with regular blood sampling. Benefit: no benefit for this pregnancy as in the study phase the result of the invasive prenatal test is leading.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Maastricht, Netherlands, 6202AZ
- Recruiting
- Maastricht UMC
-
Contact:
- Christine EM de Die, MD PhD
- Phone Number: 0031433877859 0031433877859
- Email: c.dedie@mumc.nl
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500HB
- Recruiting
- Radboud UMC
-
Contact:
- Ilse Feenstra, MD PhD
- Phone Number: 0031243653678
- Email: ilse.feenstra@radboudumc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Pregnant women and their partner (≥18y) that undergo an invasive procedure for prenatal genetic diagnosis in the MUMC+ of RUMC for one of the following indications:
- fetus at high risk of having inherited a dominant or recessive disorder of his/her affected parent(s) or
- fetus at risk of having a de novo disorder on the basis of ultrasonography findings.
Description
Inclusion Criteria:
the pregnant woman is scheduled for or has recently undergone invasive prenatal testing (regular care) because of one of the following reasons:
- the fetus is at high risk of a having inherited a single-gene disorder from his/her affected parent(s).
- the fetus is at risk of having a de dominant novo disorder on the basis of ultrasonography findings.
- the pregnant woman is 18 years or older
- the pregnant woman has sufficient understanding of Dutch language and is able to give informed consent
Exclusion Criteria:
- if in the opinion of the treating physician psychological distress is so severe that asking for participation is not safe
- the pregnant woman is treated for a malignancy
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Development of a targeted molecular test (mostly standard PCR or real-time PCR) for non-invasive prenatal testing of single-gene disorders.
Time Frame: 2014-2016
|
Main aims are to
|
2014-2016
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Christine de Die, MD PhD, Maastricht UMC
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL48304/METC azM/UM 14-02-012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hereditary Disease
-
National Eye Institute (NEI)CompletedHereditary Eye DiseaseUnited States
-
National Eye Institute (NEI)Completed
-
Seoul National University HospitalCompletedEye Diseases | Retinal Degeneration | Retinal Diseases | Retinitis Pigmentosa | Eye Disease, HereditaryKorea, Republic of
-
Brigham and Women's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedGenetic Predisposition to Disease | Hereditary DiseaseUnited States
-
Massachusetts General HospitalBroad Institute; Laboratory for Molecular MedicineCompletedGenetic Predisposition to Disease | Hereditary DiseaseUnited States
-
Vissum, Instituto Oftalmológico de AlicanteHospital Universitario La Paz; Reviva Pharmaceuticals; LASER VISION CENTER IN... and other collaboratorsUnknownKeratoconus | Hereditary Corneal DystrophyLebanon
-
Hospital de Olhos Sadalla Amin GhanemCompletedEye Diseases, Hereditary
-
Children's Hospital of Fudan UniversityRecruitingGenetic Predisposition to Disease | Newborn | Defect, Congenital | Hereditary DiseaseChina
-
University College London HospitalsCompletedDistal Hereditary Motor Neuropathy, Type II | Distal Hereditary Motor Neuropathy, Type V | Distal Hereditary Motor Neuronopathy Type I | Distal Hereditary Motor Neuronopathy Type VIUnited Kingdom
-
National Eye Institute (NEI)CompletedCorneal Dystrophies, Hereditary | Corneal DiseaseUnited States, China, Italy